Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
PREMPRO is an oral combination hormone replacement therapy (HRT) containing conjugated estrogens and medroxyprogesterone acetate (MPA), approved in 1994 for the treatment of moderate-to-severe vasomotor symptoms and vulvar/vaginal atrophy associated with menopause. The conjugated estrogens provide estrogen replacement while MPA provides progestin coverage to reduce endometrial hyperplasia risk. This combination formulation is indicated for menopausal symptom management in women with an intact uterus.
Product approaching loss of exclusivity signals career transition opportunities; teams are likely shifting focus to legacy management or next-generation HRT alternatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PREMPRO offers limited high-growth career momentum given its LOE-approaching status and minimal job openings (0 linked positions). Roles focus on protecting remaining market share, managing regulatory compliance, and supporting smooth transition to generic/competitor products.
Worked on PREMPRO (PREMARIN;CYCRIN) at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.